A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Single · Treatment
Enrollment
81actual
Sites
3
Countries
United Kingdom, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-20 | actual | When the study began enrolling |
| Primary completion | 2025-10-29 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-10-29 | actual | The whole study's end, after follow-up |
| First posted | 2024-12-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Dyslipidemia
Interventions
- Drug: AZD0780
- Drug: Ezetimibe
- Drug: Rosuvastatin
- Drug: Bempedoic Acid
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFChange from baseline in direct Low-density Lipsprotein Cholesterol (LDL-C)
measured Week 4
Number of participants with adverse events
measured From screening (Day -56 to -29) to 14 Weeks
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed